190 related articles for article (PubMed ID: 16855388)
21. BRK/Sik expression in the gastrointestinal tract and in colon tumors.
Llor X; Serfas MS; Bie W; Vasioukhin V; Polonskaia M; Derry J; Abbott CM; Tyner AL
Clin Cancer Res; 1999 Jul; 5(7):1767-77. PubMed ID: 10430081
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of protease M in ovarian tumors.
Tanimoto H; Underwood LJ; Shigemasa K; Parmley TH; O'Brien TJ
Tumour Biol; 2001; 22(1):11-8. PubMed ID: 11054022
[TBL] [Abstract][Full Text] [Related]
23. Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
Byrne JA; Balleine RL; Schoenberg Fejzo M; Mercieca J; Chiew YE; Livnat Y; St Heaps L; Peters GB; Byth K; Karlan BY; Slamon DJ; Harnett P; Defazio A
Int J Cancer; 2005 Dec; 117(6):1049-54. PubMed ID: 15986428
[TBL] [Abstract][Full Text] [Related]
24. A study detection of the ROS1 gene fusion by FISH and ROS1 protein expression by IHC methods in patients with ovarian malignant or borderline serous tumors.
Aydin HA; Pestereli E; Ozcan M; Bayramoglu Z; Erdogan G; Simsek T
Pathol Res Pract; 2018 Nov; 214(11):1868-1872. PubMed ID: 30249502
[TBL] [Abstract][Full Text] [Related]
25. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways.
Körner M; Burckhardt E; Mazzucchelli L
J Pathol; 2005 Sep; 207(1):20-6. PubMed ID: 16021676
[TBL] [Abstract][Full Text] [Related]
26. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
27. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
28. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
29. Amplification of 11q13 in ovarian carcinoma.
Brown LA; Kalloger SE; Miller MA; Shih IeM; McKinney SE; Santos JL; Swenerton K; Spellman PT; Gray J; Gilks CB; Huntsman DG
Genes Chromosomes Cancer; 2008 Jun; 47(6):481-9. PubMed ID: 18314909
[TBL] [Abstract][Full Text] [Related]
30. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
[TBL] [Abstract][Full Text] [Related]
32. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
Dong Y; Kaushal A; Bui L; Chu S; Fuller PJ; Nicklin J; Samaratunga H; Clements JA
Clin Cancer Res; 2001 Aug; 7(8):2363-71. PubMed ID: 11489814
[TBL] [Abstract][Full Text] [Related]
33. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.
Lee CH; Huntsman DG; Cheang MC; Parker RL; Brown L; Hoskins P; Miller D; Gilks CB
Int J Gynecol Pathol; 2005 Apr; 24(2):147-52. PubMed ID: 15782071
[TBL] [Abstract][Full Text] [Related]
35. H-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer.
Wang XC; Katso R; Butler R; Hanby AM; Poulsom R; Jones T; Sheer D; Ganesan TS
Mol Med; 1996 Mar; 2(2):189-203. PubMed ID: 8726462
[TBL] [Abstract][Full Text] [Related]
36. [Significance and mechanisms of overexpression of PAK1 gene in epithelial ovarian neoplasms].
Xie D; Yang GF; Chen YQ; Jiang LF; Xiao LZ
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):911-4. PubMed ID: 17533742
[TBL] [Abstract][Full Text] [Related]
37. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
Chen X; Wang X; Wei X; Wang J
J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
39. [Human pituitary tumor transforming gene 1 expression in ovarian carcinoma and its clinical significance].
Cheng YX; Feng J; Zhang XY; Fu TY; Yao Y
Ai Zheng; 2004 Sep; 23(9):1026-30. PubMed ID: 15363195
[TBL] [Abstract][Full Text] [Related]
40. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
